ANI Pharmaceuticals (STU:BSFA) Cyclically Adjusted Revenue per Share: €23.66 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BSFA ANI Pharmaceuticals Inc STU:BSFA
90 GF Score
Price €66.50
GF Value €85.37
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ANI Pharmaceuticals Cyclically Adjusted Revenue per Share?

ANI Pharmaceuticals STU:BSFA +0.76% 90 Cyclically Adjusted Revenue per Share is €23.66 as of Jun. 2026. GuruFocus rates STU:BSFA with a GF Score™ of 90/100 and a GF Value™ of €85.37 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ANI Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was €10.537. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €23.66 for the trailing ten years ended in Jun. 2026.

During the past 12 months, ANI Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 18.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 16.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ANI Pharmaceuticals was 28.40% per year. The lowest was -19.80% per year. And the median was 16.20% per year.

As of today (2026-08-20), ANI Pharmaceuticals's current stock price is €66.50. ANI Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €23.66. ANI Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.81.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ANI Pharmaceuticals was 15.69. The lowest was 1.80. And the median was 3.38.


ANI Pharmaceuticals  (STU:BSFA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ANI Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=66.50/23.66
=2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ANI Pharmaceuticals was 15.69. The lowest was 1.80. And the median was 3.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ANI Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


ANI Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ANI Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ANI Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

ANI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.26 14.41 15.57 19.08 21.16

ANI Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.98 19.94 21.16 22.39 23.66

STU:BSFA vs TRLV, AMLX, XERS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ANI Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ANI Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:BSFA
90GF Score
ANI Pharmaceuticals Inc STU:BSFA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ANI Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ANI Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=10.537/333.9520*333.9520
=10.537

Current CPI (Jun. 2026) = 333.9520.

ANI Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.953 241.428 4.085
201612 3.113 241.432 4.306
201703 2.939 243.801 4.026
201706 3.415 244.955 4.656
201709 3.461 246.819 4.683
201712 3.456 246.524 4.682
201803 3.220 249.554 4.309
201806 3.432 251.989 4.548
201809 3.681 252.439 4.870
201812 4.260 251.233 5.663
201903 3.959 254.202 5.201
201906 3.921 256.143 5.112
201909 3.857 256.759 5.017
201912 3.603 256.974 4.682
202003 3.785 258.115 4.897
202006 3.597 257.797 4.660
202009 3.747 260.280 4.808
202012 3.923 260.474 5.030
202103 3.811 264.877 4.805
202106 3.340 271.696 4.105
202109 3.655 274.310 4.450
202112 3.801 278.802 4.553
202203 3.628 287.504 4.214
202206 4.294 296.311 4.839
202209 5.193 296.808 5.843
202212 5.449 296.797 6.131
202303 6.033 301.836 6.675
202306 6.025 305.109 6.595
202309 6.459 307.789 7.008
202312 6.253 306.746 6.808
202403 6.510 312.332 6.961
202406 6.637 314.175 7.055
202409 6.888 315.301 7.295
202412 9.359 315.605 9.903
202503 9.096 319.799 9.499
202506 9.024 322.561 9.343
202509 9.202 324.800 9.461
202512 9.513 324.054 9.804
202603 9.534 330.213 9.642
202606 10.537 333.952 10.537

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €23.66 mean?
ANI Pharmaceuticals (STU:BSFA) has a Cyclically Adjusted Revenue per Share of €23.66 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ANI Pharmaceuticals and its competitors.
Is ANI Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
ANI Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €23.66. Overall, ANI Pharmaceuticals has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to TRLV and AMLX?
ANI Pharmaceuticals' Cyclically Adjusted Revenue per Share of €23.66 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ANI Pharmaceuticals and its competitors. ANI Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €23.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (STU:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €85.37, compared to a current price of €66.50 — trading 22.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €23.66. ANI Pharmaceuticals' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ANI Pharmaceuticals (STU:BSFA), the current Cyclically Adjusted Revenue per Share is €23.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ANI Pharmaceuticals (STU:BSFA) Overvalued in 2026?

Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued. The current stock price of €66.50 is trading 22.1% below its estimated GF Value™ of €85.37. GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:BSFA:

  • Cyclically Adjusted Revenue per Share: €23.66
  • GF Value™: €85.37 vs. price of €66.50 (22.1% below fair value)
  • GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the STU:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ANI Pharmaceuticals Business Description

Other Exchanges ANIP:USABSFA:Germany
Address 210 Main Street West, Baudette, MN, USA, 56623
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
90GF Score

Get the complete analysis for STU:BSFA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.50
Price
€85.37
GF Value